Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801747 | 0.89 | GRIN2B (0.48) | GRIN2BGRIN2CMMP2MMP13MMP14 | |
| SCHEMBL30801691 | 0.82 | GRIN2B (0.53) | GRIN2BGRIN2CMMP2MMP13MMP14 | |
| SCHEMBL19839379 | 0.81 | GRIN2B (0.38) | GRIN2BGRIN2C | |
| SCHEMBL19839374 | 0.81 | GRIN2B (0.38) | GRIN2BGRIN2C | |
| SCHEMBL24338396 | 0.81 | GRIN2B (0.45) | GRIN2BGRIN2C | |
| SCHEMBL30801693 | 0.80 | GRIN2B (0.47) | GRIN2BGRIN2C | |
| SCHEMBL23342004 | 0.78 | ACACB (0.38) | MMP2MMP13MMP14ADAM17 | |
| SCHEMBL23342003 | 0.77 | ACACB (0.34) | GRIN2BGRIN2CMMP2MMP13MMP14 | |
| SCHEMBL23346959 | 0.76 | GRIN2B (0.56) | GRIN2BGRIN2CJAK3 | |
| SCHEMBL19839353 | 0.73 | GRIN2B (0.34) | GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |